596 A randomised phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear cell carcinoma of the ovary or endometrium. (NICCC/ENGOT-OV36)
596 A randomised phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear cell carcinoma of the ovary or endometrium. (NICCC/ENGOT-OV36)